MedTrace Logo

Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

NCT02761070 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2023-03-08

No results posted yet for this study

Summary

The aim of this Phase III study is to evaluate the superiority of dose-dense temozolomide (ddTMZ) followed by bevacizumab at ddTMZ failure for glioblastoma at first recurrence or progression, comparing to bevacizumab alone.

Conditions

Interventions

DRUG

Temozolomide

DRUG

Bevacizumab

Sponsors & Collaborators

  • Japan Clinical Oncology Group

    collaborator OTHER

  • Kyorin University

    lead OTHER

Principal Investigators

  • Motoo Nagane, M.D., Ph.D. · Kyorin University Faculty of Medicine, Department of Neurosurgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-11
Primary Completion
2025-11-10
Completion
2025-11-10

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02761070 on ClinicalTrials.gov